advertisement
Topouzis F 9
Showing records 1 to 9 | Display all abstracts from Topouzis F122711 Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension
Erb C
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
119227 Expert Consensus Recommendations for the Management of Ocular Surface Inflammation in Patients With Glaucoma
Messmer EM; Baudouin C
Journal of Glaucoma 2024; 33: 715-727
122711 Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension
Topouzis F; Jayaram H
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
119227 Expert Consensus Recommendations for the Management of Ocular Surface Inflammation in Patients With Glaucoma
Benitez-del-Castillo JM; Iester M
Journal of Glaucoma 2024; 33: 715-727
122711 Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension
Allan F; Nisslé S
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
119227 Expert Consensus Recommendations for the Management of Ocular Surface Inflammation in Patients With Glaucoma
Anton A; Thygesen J
Journal of Glaucoma 2024; 33: 715-727
122711 Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension
Muñoz-Negrete FJ
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
119227 Expert Consensus Recommendations for the Management of Ocular Surface Inflammation in Patients With Glaucoma
Topouzis F
Journal of Glaucoma 2024; 33: 715-727
122711 Preclinical and Clinical Pharmacokinetics of a New Preservative-Free Bimatoprost 0.01% Ophthalmic Gel to Treat Glaucoma and Ocular Hypertension
Stalmans I
Journal of Ocular Pharmacology and Therapeutics 2024; 0: